ACORN BIOVENTURES, L.P. 13D and 13G filings for Cyclacel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-07 5:03 pm Sale |
2023-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC |
ACORN BIOVENTURES, L.P. | 0 0.000% |
-187,676 (Position Closed) |
Filing |
| 2023-01-26 1:36 pm Purchase |
2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC |
ACORN BIOVENTURES, L.P. | 187,676 9.990% |
31,377 (+20.07%) |
Filing |
| 2021-02-12 4:58 pm Purchase |
2020-12-18 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC |
ACORN BIOVENTURES, L.P. | 156,299 9.990% |
156,299 (New Position) |
Filing |